Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO-B in transthyretin amyloidosis with cardiomyopathy
jRCT2031210085Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2020
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Patisiran with Placebo (2 arms). Primary endpoint: Change from baseline at Month 12 in 6-minute walk test distance. Started Jul 2020; status: active, not recruiting.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on jRCT2031210085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210085.